STAT3 and rectal cancer: We recently demonstrated that perturbation of STAT3 signaling using either RNAi or the STAT3 inhibitor napabucasin re-sensitized treatment-refractory rectal cancer cells to CRT and abolished tumor growth in vivo [22].